Healthcare
Lexeo Therapeutics, Inc. Common Stock(LXEO)
Live Price
Offline$4.93
-1.00% today
1Y Change
+13.37%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $430.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +39.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Lexeo Therapeutics, Inc. Common Stock (LXEO) is a Healthcare stock with a market cap of $430.00M and listed on NASDAQ. The stock last traded around $4.93 and up 13.4% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +39.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +39.8%, free cash flow -21.2% with operating margin 0.0% and ROIC -42.9%. Stock Foundry combines LXEO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +39.8%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | -6.9% | -23.0% | -30.7% |
2026 Mar 30, 2026 | +15.6% | +8.9% | +19.7% | +10.2% |
2025 Nov 5, 2025 | +31.3% | +2.7% | +12.3% | +10.9% |
Benchmark Edge
LXEO vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LXEO
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LXEO Max Drawdown
-61.15%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for LXEO and SPY.
Company Overview
Lexeo Therapeutics, Inc. Common Stock
NASDAQ Global Market
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
- Leadership
- R. Nolan Townsend
- IPO Date
- Nov 3, 2023
- Employees
- 75
- Street Address
- 345 Park Avenue South
- Mailing
- New York City, 10010
- Region
- New York City, US
- Reporting Currency
- USD
- Investor Line
- 212-547-9879
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.8
Growth
- Revenue
- 0.0%
- EPS
- +39.8%
- Free Cash Flow
- -21.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -67.3%
- ROIC
- -42.9%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 11.21
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.